Critical

ANCA-associated (pauci-immune) vasculitis with renal involvement

ANCA vasculitis · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Small-vessel vasculitis (GPA, MPA, EGPA) causing pauci-immune necrotising crescentic glomerulonephritis, often with rapidly progressive AKI and pulmonary involvement. Requires urgent immunosuppression to preserve kidney function and treat life-threatening features.

Red flags

  • Haemoptysis / diffuse alveolar haemorrhage
  • Rapidly rising creatinine or oligo-anuria
  • Mononeuritis multiplex or neurological involvement
  • Severe sepsis on immunosuppression
  • Scleritis, saddle-nose or subglottic stenosis (GPA)
  • Coexisting anti-GBM positivity (double-positive)

Assessment

Differential diagnosis

  • Granulomatosis with polyangiitis (GPA)
  • Microscopic polyangiitis (MPA)
  • Eosinophilic granulomatosis with polyangiitis (EGPA)
  • Anti-GBM disease (can coexist)
  • Lupus nephritis / immune-complex GN
  • Infective endocarditis-related GN

Investigations

  • ANCA (PR3 and MPO by ELISA)
  • Urinalysis with microscopy for dysmorphic RBCs/casts and urine ACR/PCR
  • U&E, creatinine trend and FBC/CRP
  • Anti-GBM antibody, ANA/dsDNA, complement (to exclude mimics)
  • Chest imaging (CXR/CT) for pulmonary haemorrhage/nodules
  • Renal biopsy for crescentic pauci-immune GN

Management

  • Recognise RPGN pattern: rising creatinine with haematuria, red cell casts and proteinuria — treat as emergency
  • Send urgent ANCA, anti-GBM and complement; arrange renal biopsy without delaying treatment in severe disease
  • Assess for organ/life-threatening features: pulmonary haemorrhage, severe/dialysis-requiring AKI, alveolar bleeding
  • Start high-dose glucocorticoids immediately (IV methylprednisolone pulses then oral prednisolone taper)
  • Induce remission with rituximab or cyclophosphamide alongside steroids
  • Use plasma exchange for diffuse alveolar haemorrhage or severe renal failure (dialysis-dependent/rapidly rising creatinine), per MEPEX/PEXIVAS-guided selection
  • Give PCP prophylaxis (co-trimoxazole) and gastroprotection; screen for infection/TB/hepatitis before immunosuppression
  • Support failing kidneys: manage AKI complications, dialysis if indicated
  • Transition to maintenance immunosuppression (rituximab or azathioprine) after remission
  • Taper steroids using a reduced-dose regimen (PEXIVAS-style) to limit toxicity
  • Monitor ANCA titres, renal function and for relapse
  • Address long-term cardiovascular, bone and infection-prophylaxis needs

Drugs & doses

Methylprednisolone 500 mg IV daily for 3 days (pulse induction)
Prednisolone 1 mg/kg/day PO (max 60-80 mg) then reduced-dose PEXIVAS taper
Rituximab 375 mg/m2 IV weekly x4 OR 1 g IV on days 0 and 14
Cyclophosphamide IV 15 mg/kg (max 1.2 g) every 2-3 weeks (dose-reduced for age/renal function) OR 2 mg/kg/day PO
Co-trimoxazole 480-960 mg PO daily (PCP prophylaxis)
Azathioprine 2 mg/kg/day PO (maintenance alternative)

Disposition

Admit under nephrology/rheumatology; urgent discussion with specialist vasculitis service. ICU/respiratory support for alveolar haemorrhage. Renal replacement if indicated.

Complications & pitfalls

  • Irreversible renal failure requiring dialysis
  • Fatal pulmonary haemorrhage
  • Immunosuppression-related infection (incl. PCP)
  • Relapse
  • Subglottic/tracheal stenosis (GPA)
  • Treatment toxicity (cyclophosphamide, steroids)

Exam pearls

  • RPGN is a nephrological emergency — do not wait for biopsy to start steroids in severe disease
  • Always check anti-GBM: double-positive patients exist and need plasma exchange
  • Rituximab is at least as effective as cyclophosphamide and preferred for relapsing/fertility concerns
  • Reduced-dose steroid tapers (PEXIVAS) cut infection without losing efficacy
  • Reserve plasma exchange for alveolar haemorrhage or severe/dialysis-requiring renal disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.